Drugs Disributed by Eisai Israel Ltd
Orexin Receptor Antagonist. Lemborexant 5 mg, 10 mg. FC. Tabs. X28
Recommended dosage is 5 mg, no more than once/night, immediately before going to bed, with at least 7 hs remaining before the planned time of awakening. The dose may be incr. to the max. of 10 mg based on clinical response and tolerab. Time to sleep onset may be delayed if taken with or soon after a meal.
Tmt of adults with insomnia, characterized by difficulties with sleep onset and/or sleep mainten.
C/I:Hypersens. Narcolepsy.
Antineoplastic. eribulin 0.44 mg/ml. VIAL. Sol. for IV inj. 1/6 X 2 ml (0.88 mg eribulin)
Ready to use sol.: 1.23 mg/m2 to be admin. intrav. over 2 to 5 min on Days 1 and 8 of every 21-day cycle.
Tmt. of adlt pts with locally adv. or metast. breast cancer who have progressed after at least one chemotherap. regimen for adv. dis. Prior ther. should have incl. an anthracycline and a taxane in either the adj. or metast. setting unless pts were not suitable for these tmts. For the tmt of adlt pts with unresectable liposarcoma who have received prior anthracycline cont. ther. (unless unsuitable) for adv. or metast. dis..
C/I: Hypersens. Breastfeed.
Monoclonal Antibody. Lecanemab 100 mg/ml. Vial. Conc. for sol. for inf.1 X 2/5 ml
10 mg/kg to be diluted then admin. as an IV infus. over approx. one hour, once every two weeks
Tmt. of Alzheimer’s dis.To be initiated in pts. with mild cognitive impairment or mild dementia stage of dis., the population in which tmt. was initiated in clinical trials:
C/I:Hypersens. Reactions have included angioedema and anaphylaxis.
